{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:48:34Z","timestamp":1791236914322,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005389","name":"University of Insubria","doi-asserted-by":"crossref","award":["Institutional grant 2017"],"award-info":[{"award-number":["Institutional grant 2017"]}],"id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005389","name":"University of Insubria","doi-asserted-by":"crossref","award":["FAR 2016"],"award-info":[{"award-number":["FAR 2016"]}],"id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005389","name":"University of Insubria","doi-asserted-by":"crossref","award":["2017"],"award-info":[{"award-number":["2017"]}],"id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005389","name":"University of Insubria","doi-asserted-by":"crossref","award":["FAR 2016"],"award-info":[{"award-number":["FAR 2016"]}],"id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005389","name":"University of Insubria","doi-asserted-by":"crossref","award":["2017"],"award-info":[{"award-number":["2017"]}],"id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Community FP7","award":["602893 HepaVac"],"award-info":[{"award-number":["602893 HepaVac"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunity against pathogens evolved through complex mechanisms that only for sake of simplicity are defined as innate immunity and adaptive immunity. Indeed innate and adaptive immunity are strongly intertwined each other during evolution. The complexity is further increased by intrinsic mechanisms of immunity that rely on the action of intracellular molecules defined as restriction factors (RFs) that, particularly in virus infections, counteract the action of pathogen gene products acting at different steps of virus life cycle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body and conclusion<\/jats:title>\n                <jats:p>Here we provide an overview on the nature and the mode of action of restriction factors involved in retrovirus infection, particularly Human T Leukemia\/Lymphoma Virus 1 (HTLV-1) infection. As it has been extensively studied by our group, special emphasis is given to the involvement of the MHC class II transactivator CIITA discovered in our laboratory as regulator of adaptive immunity and subsequently as restriction factor against HIV-1 and HTLV-1, a unique example of dual function linking adaptive and intrinsic immunity during evolution. We describe the multiple molecular mechanisms through which CIITA exerts its restriction on retroviruses. Of relevance, we review the unprecedented findings pointing to a concerted action of several restriction factors such as CIITA, TRIM22 and TRIM19\/PML in synergizing against retroviral replication. Finally, as CIITA profoundly affects HTLV-1 replication by interacting and inhibiting the function of HTLV-1 Tax-1 molecule, the major viral product associated to the virus oncogenicity, we also put forward the hypothesis of CIITA as counteractor of HTLV-1-mediated cancer initiation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12977-019-0498-6","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T16:02:48Z","timestamp":1575043368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1"],"prefix":"10.1186","volume":"16","author":[{"given":"Greta","family":"Forlani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Shallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Ramia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-7378","authenticated-orcid":false,"given":"Roberto S.","family":"Accolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"issue":"1","key":"498_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-virology-110615-042323","volume":"4","author":"MJ Roossinck","year":"2017","unstructured":"Roossinck MJ, Baz\u00e1n ER. Symbiosis: viruses as intimate partners. Ann Rev Virol. 2017;4(1):123\u201339.","journal-title":"Ann Rev Virol"},{"issue":"1","key":"498_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.chom.2018.12.006","volume":"25","author":"MG Netea","year":"2019","unstructured":"Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. Innate and adaptive immune memory: an evolutionary continuum in the host\u2019s response to pathogens. Cell Host Microbe. 2019;25(1):13\u201326.","journal-title":"Cell Host Microbe"},{"issue":"2","key":"498_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/imm.12597","volume":"148","author":"M Riera Romo","year":"2016","unstructured":"Riera Romo M, P\u00e9rez-Mart\u00ednez D, Castillo Ferrer C. Innate immunity in vertebrates: an overview. Immunology. 2016;148(2):125\u201339.","journal-title":"Immunology"},{"issue":"10","key":"498_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S1471-4906(01)02003-8","volume":"22","author":"RS Accolla","year":"2001","unstructured":"Accolla RS, De Lerma Barbaro A, Mazza S, Casoli C, De Maria A, Tosi G. The MHC class II transactivator: prey and hunter in infectious diseases. Trends Immunol. 2001;22(10):560\u20133.","journal-title":"Trends Immunol."},{"issue":"11","key":"498_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ni1125","volume":"5","author":"P Bieniasz","year":"2004","unstructured":"Bieniasz P. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol. 2004;5(11):1109\u201315.","journal-title":"Nat Immunol"},{"issue":"5","key":"498_CR6","doi-asserted-by":"publisher","first-page":"a006940","DOI":"10.1101\/cshperspect.a006940","volume":"2","author":"M Malim","year":"2012","unstructured":"Malim M, Bieniasz P. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med. 2012;2(5):a006940.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"498_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ni.3156","volume":"6","author":"V Simon","year":"2015","unstructured":"Simon V, Bloch N, Landau N. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol. 2015;6:546\u201353.","journal-title":"Nat Immunol"},{"key":"498_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev.genet.42.110807.091704","volume":"42","author":"D Wolf","year":"2008","unstructured":"Wolf D, Goff SP. Host restriction factors blocking retroviral replication. Annu Rev Genet. 2008;42:143\u201363.","journal-title":"Annu Rev Genet"},{"issue":"2","key":"498_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.chom.2012.01.007","volume":"11","author":"N Laguette","year":"2012","unstructured":"Laguette N, Rahm N, Sobhian B, Chable-Bessia C, M\u00fcnch J, Snoeck J, et al. Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe. 2012;11(2):205\u201317.","journal-title":"Cell Host Microbe"},{"issue":"106","key":"498_CR10","first-page":"14","volume":"31","author":"X Jia","year":"2015","unstructured":"Jia X, Zhao Q, Xiong Y. HIV suppression by host restriction factors and immune evasion. Curr Opin Struct Biol. 2015;31(106):14.","journal-title":"Curr Opin Struct Biol"},{"issue":"4","key":"498_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0092-8674(04)00163-1","volume":"116","author":"R Harris","year":"2003","unstructured":"Harris R, Bishop K, Sheehy A, Craig H, Petersen-Mahrt S, Watt I, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;116(4):629.","journal-title":"Cell"},{"issue":"6977","key":"498_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nature02343","volume":"427","author":"M Stremlau","year":"2004","unstructured":"Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5\u03b1 restricts HIV-1 infection in Old World monkeys. Nature. 2004;427(6977):848\u201353.","journal-title":"Nature"},{"issue":"29","key":"498_CR13","doi-asserted-by":"publisher","first-page":"10774","DOI":"10.1073\/pnas.0402361101","volume":"101","author":"T Hatziioannou","year":"2004","unstructured":"Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA. 2004;101(29):10774\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"498_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature06553","volume":"451","author":"SJD Neil","year":"2008","unstructured":"Neil SJD, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451:425.","journal-title":"Nature"},{"issue":"4","key":"498_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","volume":"3","author":"N Van Damme","year":"2008","unstructured":"Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008;3(4):245\u201352.","journal-title":"Cell Host Microbe"},{"issue":"7353","key":"498_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nature10117","volume":"474","author":"N Laguette","year":"2011","unstructured":"Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, S\u00e9g\u00e9ral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654\u20137.","journal-title":"Nature"},{"issue":"6898","key":"498_CR17","first-page":"646","volume":"418","author":"A Sheehy","year":"2002","unstructured":"Sheehy A, Gaddis N, Choi J, Malim M. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nat Immunol. 2002;418(6898):646\u201350.","journal-title":"Nat Immunol"},{"issue":"6944","key":"498_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature01709","volume":"424","author":"B Mangeat","year":"2003","unstructured":"Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424(6944):99\u2013103.","journal-title":"Nature"},{"issue":"1","key":"498_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0092-8674(03)00515-4","volume":"114","author":"R Mariani","year":"2003","unstructured":"Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114(1):21\u201331.","journal-title":"Cell"},{"issue":"15","key":"498_CR20","doi-asserted-by":"publisher","first-page":"8238","DOI":"10.1128\/JVI.78.15.8238-8244.2004","volume":"78","author":"M Kobayashi","year":"2004","unstructured":"Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T. APOBEC3G targets specific virus species. J Virol. 2004;78(15):8238\u201344.","journal-title":"J Virol"},{"issue":"13","key":"498_CR21","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.1128\/JVI.79.13.8201-8207.2005","volume":"79","author":"B Doehle","year":"2005","unstructured":"Doehle B, Schafer A, Wiegand H, Bogerd H, Cullen B. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol. 2005;79(13):8201\u20137.","journal-title":"J Virol."},{"issue":"14","key":"498_CR22","doi-asserted-by":"publisher","first-page":"8724","DOI":"10.1128\/JVI.79.14.8724-8731.2005","volume":"79","author":"R Russell","year":"2005","unstructured":"Russell R, Wiegand H, Moore M, Schafer A, McClure M, Cullen B. Foamy virus bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. JVirol. 2005;79(14):8724\u201331.","journal-title":"JVirol."},{"issue":"5665","key":"498_CR23","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1126\/science.1092066","volume":"303","author":"P Turelli","year":"2004","unstructured":"Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science. 2004;303(5665):1829.","journal-title":"Science."},{"issue":"Pt 9","key":"498_CR24","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1099\/vir.0.80973-0","volume":"86","author":"R Mahieux","year":"2005","unstructured":"Mahieux R, Suspene R, Delebecque F, Henry M, Schwartz O, Wain-Hobson S, et al. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J Gen Virol. 2005;86(Pt 9):2489\u201394.","journal-title":"J Gen Virol"},{"issue":"2","key":"498_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.virol.2005.01.011","volume":"333","author":"F Navarro","year":"2005","unstructured":"Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, et al. Complementary function of the two catalytic domains of APOBEC3G. Virology. 2005;333(2):374\u201386.","journal-title":"Virology"},{"issue":"8","key":"498_CR26","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1073\/pnas.0609444104","volume":"104","author":"D Derse","year":"2007","unstructured":"Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci USA. 2007;104(8):2915\u201320.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"14","key":"498_CR27","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1128\/JVI.02239-09","volume":"84","author":"J Fan","year":"2010","unstructured":"Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, et al. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol. 2010;84(14):7278\u201387.","journal-title":"J Virol"},{"issue":"7353","key":"498_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature10195","volume":"474","author":"K Hrecka","year":"2011","unstructured":"Hrecka K, Hao C, Gierszewska M, Swanson S, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658\u201361.","journal-title":"Nature"},{"issue":"7","key":"498_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng.373","volume":"41","author":"GI Rice","year":"2009","unstructured":"Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. Mutations involved in Aicardi-Gouti\u00e8res syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41(7):829\u201332.","journal-title":"Nat Genet"},{"key":"498_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1742-4690-9-87","volume":"9","author":"B Descours","year":"2012","unstructured":"Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012;9:87.","journal-title":"Retrovirology."},{"issue":"24","key":"498_CR31","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1016\/j.jmb.2013.09.029","volume":"425","author":"D Hotter","year":"2013","unstructured":"Hotter D, Sauter D, Kirchhoff F. Emerging role of the host restriction factor tetherin in viral immune sensing. J Mol Biol. 2013;425(24):4956\u201364.","journal-title":"J Mol Biol"},{"issue":"2","key":"498_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.chom.2016.06.007","volume":"20","author":"D Blanco-Melo","year":"2016","unstructured":"Blanco-Melo D, Venkatesh S, Bieniasz PD. Origins and evolution of tetherin, an orphan antiviral gene. Cell Host Microbe. 2016;20(2):189\u2013201.","journal-title":"Cell Host Microbe"},{"issue":"6","key":"498_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jmb.2013.12.005","volume":"426","author":"R Rajsbaum","year":"2014","unstructured":"Rajsbaum R, Garc\u00eda-Sastre A, Versteeg GA. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol. 2014;426(6):1265\u201384.","journal-title":"J Mol Biol"},{"issue":"11","key":"498_CR34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nri2413","volume":"8","author":"K Ozato","year":"2008","unstructured":"Ozato K, Shin D, Chang T, Morse HR. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8(11):849\u201360.","journal-title":"Nat Rev Immunol."},{"issue":"10","key":"498_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nrmicro1248","volume":"3","author":"S Nisole","year":"2005","unstructured":"Nisole S, Stoye J, Sa\u00efb A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol. 2005;3(10):799\u2013808.","journal-title":"Nat Rev Microbiol"},{"issue":"25","key":"498_CR36","doi-asserted-by":"publisher","first-page":"14891","DOI":"10.1074\/jbc.270.25.14891","volume":"270","author":"C Tissot","year":"1995","unstructured":"Tissot C, Mechti N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem. 1995;270(25):14891\u20138.","journal-title":"J Biol Chem"},{"issue":"14","key":"498_CR37","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1073\/pnas.0509996103","volume":"103","author":"M Stremlau","year":"2006","unstructured":"Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA. 2006;103(14):5514\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"498_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nm1562","volume":"13","author":"R Sakuma","year":"2007","unstructured":"Sakuma R, Noser J, Ohmine S, Ikeda Y. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med. 2007;13(5):631\u20135.","journal-title":"Nat Med."},{"key":"498_CR39","doi-asserted-by":"publisher","first-page":"426840","DOI":"10.1155\/2012\/426840","volume":"2012","author":"J Luban","year":"2012","unstructured":"Luban J. TRIM5 and the regulation of HIV-1 infectivity. Mol Biol Int. 2012;2012:426840.","journal-title":"Mol Biol Int."},{"issue":"21","key":"498_CR40","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41388-018-0163-x","volume":"37","author":"L Dubuisson","year":"2018","unstructured":"Dubuisson L, Lormi\u00e8res F, Fochi S, Turpin J, Pasquier A, Douceron E, et al. Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner. Oncogene. 2018;37(21):2806\u201316.","journal-title":"Oncogene"},{"issue":"2","key":"498_CR41","doi-asserted-by":"publisher","first-page":"e1000007","DOI":"10.1371\/journal.ppat.1000007","volume":"4","author":"S Barr","year":"2008","unstructured":"Barr S, Smiley J, Bushman F. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 2008;4(2):e1000007.","journal-title":"PLoS Pathog"},{"issue":"10","key":"498_CR42","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1128\/JVI.02302-10","volume":"85","author":"A Kajaste-Rudnitski","year":"2011","unstructured":"Kajaste-Rudnitski A, Marelli S, Pultrone C, Pertel T, Uchil P, Mechti N, et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol. 2011;85(10):5183\u201396.","journal-title":"J Virol"},{"key":"498_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12985-015-0335-z","volume":"12","author":"F Turrini","year":"2015","unstructured":"Turrini F, Marelli S, Kajaste-Rudnitski A, Lusic M, Van Lint C, Das A, et al. HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. J Virol. 2015;12:104.","journal-title":"J Virol"},{"key":"498_CR44","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3389\/fimmu.2017.00564","volume":"8","author":"G Forlani","year":"2017","unstructured":"Forlani G, Tosi G, Turrini F, Poli G, Vicenzi E, Accolla RS. Tripartite motif-containing protein 22 interacts with class II transactivator and orchestrates its recruitment in nuclear bodies containing TRIM19\/PML and cyclin T1. Front Immunol. 2017;8:564.","journal-title":"Front Immunol"},{"key":"498_CR45","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fimmu.2017.01362","volume":"8","author":"G Forlani","year":"2017","unstructured":"Forlani G, Accolla RS. Tripartite motif 22 and class II transactivator restriction factors: unveiling their concerted action against retroviruses. Front Immunol. 2017;8:1362.","journal-title":"Front Immunol."},{"issue":"1","key":"498_CR46","doi-asserted-by":"publisher","first-page":"14249","DOI":"10.1038\/s41598-018-32451-w","volume":"8","author":"F Graziano","year":"2018","unstructured":"Graziano F, Aimola G, Forlani G, Turrini F, Accolla RS, Vicenzi E, et al. Reversible human immunodeficiency virus type-1 latency in primary human monocyte-derived macrophages induced by sustained M1 polarization. Sci Rep. 2018;8(1):14249.","journal-title":"Sci Rep."},{"key":"498_CR47","doi-asserted-by":"publisher","first-page":"197631","DOI":"10.1016\/j.virusres.2019.05.009","volume":"269","author":"F Turrini","year":"2019","unstructured":"Turrini F, Saliu F, Forlani G, Das A, Van Lint C, Accolla RS, et al. Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. Virus Res. 2019;269:197631.","journal-title":"Virus Res."},{"issue":"8","key":"498_CR48","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1128\/JVI.02548-12","volume":"87","author":"A Di Pietro","year":"2013","unstructured":"Di Pietro A, Kajaste-Rudnitski A, Oteiza A, Nicora L, Towers G, Mechti N, et al. TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol. 2013;87(8):4523\u201333.","journal-title":"J Virol"},{"issue":"2","key":"498_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hep.23011","volume":"50","author":"B Gao","year":"2009","unstructured":"Gao B, Duan Z, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology. 2009;50(2):424\u201333.","journal-title":"Hepatology"},{"issue":"1","key":"498_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/cmi.2014.131","volume":"13","author":"C Yang","year":"2016","unstructured":"Yang C, Zhao X, Sun D, Yang L, Chong C, Pan Y, et al. Interferon alpha (IFN\u03b1)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol. 2016;13(1):94\u2013102.","journal-title":"Cell Mol Immunol"},{"issue":"Pt3","key":"498_CR51","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1099\/vir.0.006288-0","volume":"90","author":"P Eldin","year":"2009","unstructured":"Eldin P, Papon L, Oteiza A, Brocchi E, Lawson T, Mechti N. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol. 2009;90(Pt3):536\u201345.","journal-title":"J Gen Virol"},{"key":"498_CR52","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.3389\/fimmu.2018.02876","volume":"9","author":"M Colomer-Lluch","year":"2018","unstructured":"Colomer-Lluch M, Ruiz A, Moris A, Prado J. Restriction factors: from intrinsic viral restriction to shaping cellular immunity against HIV-1. Front Immunol. 2018;9:2876.","journal-title":"Front Immunol."},{"key":"498_CR53","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"498_CR54","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031\u201320135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"498_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2012.09.035","volume":"435","author":"A Gessain","year":"2013","unstructured":"Gessain A, Rua R, Betsem E, Turpin J, Mahieux R. HTLV-3\/4 and simian foamy retroviruses in humans: discovery, epidemiology, cross-species transmission and molecular virology. Virology. 2013;435(1):187\u20139.","journal-title":"Virology"},{"key":"498_CR56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol"},{"issue":"3","key":"498_CR57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/v8030074","volume":"8","author":"C Gross","year":"2016","unstructured":"Gross C, Thoma-Kress A. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8(3):74.","journal-title":"Viruses."},{"issue":"4","key":"498_CR58","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm1745","volume":"14","author":"K Jones","year":"2008","unstructured":"Jones K, Petrow-Sadowski C, Huang Y, Bertolette D, Ruscetti F. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med. 2008;14(4):429\u201336.","journal-title":"Nat Med"},{"key":"498_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fmicb.2018.00461","volume":"9","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Matsuoka M. HTLV-1 alters T cells for viral persistence and transmission. Front Microbiol. 2018;9:461.","journal-title":"Front Microbiol."},{"issue":"20","key":"498_CR60","doi-asserted-by":"publisher","first-page":"10580","DOI":"10.1128\/JVI.01799-15","volume":"89","author":"S Alais","year":"2015","unstructured":"Alais S, Mahieux R, Dutartre H. Viral source-independent high susceptibility of dendritic cells to human T-cell leukemia virus type 1 infection compared to that of T lymphocytes. J Virol. 2015;89(20):10580.","journal-title":"J Virol"},{"issue":"17","key":"498_CR61","doi-asserted-by":"publisher","first-page":"7607","DOI":"10.1128\/JVI.00407-16","volume":"90","author":"H Dutartre","year":"2016","unstructured":"Dutartre H, Clavi\u00e8re M, Journo C, Mahieux R. Cell-free versus cell-to-cell infection by human immunodeficiency virus type 1 and human T-lymphotropic virus type 1: exploring the link among viral source, viral trafficking, and viral replication. J Virol. 2016;90(17):7607\u201317.","journal-title":"J Virol"},{"issue":"8452","key":"498_CR62","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","volume":"2","author":"A Gessain","year":"1985","unstructured":"Gessain A, Barin F, Vernant J, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452):407\u201310.","journal-title":"Lancet"},{"issue":"8488","key":"498_CR63","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","volume":"1","author":"M Osame","year":"1986","unstructured":"Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1(8488):1031\u20132.","journal-title":"Lancet"},{"issue":"4","key":"498_CR64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka M, Jeang K. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270\u201380.","journal-title":"Nat Rev Cancer"},{"key":"498_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1742-4690-6-71","volume":"6","author":"M Matsuoka","year":"2009","unstructured":"Matsuoka M, Green P. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology. 2009;6:71.","journal-title":"Retrovirology."},{"issue":"12","key":"498_CR66","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/onc.2010.537","volume":"30","author":"M Matsuoka","year":"2011","unstructured":"Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30(12):1379\u201389.","journal-title":"Oncogene"},{"issue":"4","key":"498_CR67","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nm1389","volume":"12","author":"H Hasegawa","year":"2006","unstructured":"Hasegawa H, Sawa H, Lewis M, Orba Y, Sheehy N, Yamamoto Y, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12(4):466\u201372.","journal-title":"Nat Med"},{"issue":"4820","key":"498_CR68","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.2888190","volume":"237","author":"M Nerenberg","year":"1987","unstructured":"Nerenberg M, Hinrichs S, Reynolds R, Khoury G, Jay G. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science. 1987;237(4820):1324\u20139.","journal-title":"Science"},{"issue":"4","key":"498_CR69","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1073\/pnas.92.4.1057","volume":"92","author":"W Grossman","year":"1995","unstructured":"Grossman W, Kimata J, Wong F, Zutter M, Ley T, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92(4):1057\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"498_CR70","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ijc.20007","volume":"109","author":"S Takeda","year":"2004","unstructured":"Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J-i, Nosaka K, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109(4):559\u201367.","journal-title":"Int J Cancer."},{"key":"498_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fmicb.2012.00247","volume":"3","author":"T Zhao","year":"2012","unstructured":"Zhao T, Matsuoka M. HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol. 2012;3:247.","journal-title":"Front Microbiol."},{"key":"498_CR72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12977-016-0249-x","volume":"13","author":"G Ma","year":"2016","unstructured":"Ma G, Yasunaga J-I, Matsuoka M. Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. Retrovirology. 2016;13:16.","journal-title":"Retrovirology"},{"issue":"1","key":"498_CR73","doi-asserted-by":"publisher","first-page":"e0005285","DOI":"10.1371\/journal.pntd.0005285","volume":"11","author":"M Baratella","year":"2017","unstructured":"Baratella M, Forlani G, Raval G, Tedeschi A, Gout O, Gessain A, et al. Cytoplasmic localization of HTLV-1 HBZ protein: a biomarker of HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). PLoS Negl Trop Dis. 2017;11(1):e0005285.","journal-title":"PLoS Negl Trop Dis."},{"key":"498_CR74","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3389\/fmicb.2017.02615","volume":"8","author":"M Baratella","year":"2017","unstructured":"Baratella M, Forlani G, Accolla RS. HTLV-1 HBZ viral protein: a key player in HTLV-1 mediated diseases. Front Microbiol. 2017;8:2615.","journal-title":"Front Microbiol."},{"key":"498_CR75","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3389\/fmicb.2019.00819","volume":"10","author":"G Forlani","year":"2019","unstructured":"Forlani G, Baratella M, Tedeschi A, Pique C, Jacobson S, Accolla RS. HTLV-1 HBZ protein resides exclusively in the cytoplasm of infected cells in asymptomatic carriers and HAM\/TSP patients. Front Microbiol. 2019;10:819.","journal-title":"Front Microbiol."},{"issue":"1","key":"498_CR76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.it.2007.09.006","volume":"29","author":"B Asquith","year":"2008","unstructured":"Asquith B, Bangham C. How does HTLV-I persist despite a strong cell-mediated immune response? Trends Immunol. 2008;29(1):4\u201311.","journal-title":"Trends Immunol"},{"key":"498_CR77","doi-asserted-by":"publisher","first-page":"87","DOI":"10.12688\/wellcomeopenres.12469.1","volume":"2","author":"M Billman","year":"2017","unstructured":"Billman M, Rueda D, Bangham C. Single-cell heterogeneity and cell-cycle-related viral gene bursts in the human leukaemia virus HTLV-1. Wellcome Open Res. 2017;2:87.","journal-title":"Wellcome Open Res."},{"issue":"1","key":"498_CR78","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1034\/j.1600-065X.2002.18520.x","volume":"185","author":"RC Gallo","year":"2002","unstructured":"Gallo RC. Human retroviruses after 20\u00a0years: a perspective from the past and prospects for their future control. Immunol Rev. 2002;185(1):236\u201365.","journal-title":"Immunol Rev"},{"key":"498_CR79","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-4690-2-32","volume":"2","author":"A Sasada","year":"2005","unstructured":"Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, et al. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology. 2005;2:32.","journal-title":"Retrovirology."},{"issue":"5","key":"498_CR80","first-page":"3701","volume":"17","author":"J Yao","year":"2019","unstructured":"Yao J, Tanaka M, Takenouchi N, Ren Y, Lee S, Fujisawa J. Induction of APOBEC3B cytidine deaminase in HTLV-1-infected humanized mice. Exp Ther Med. 2019;17(5):3701\u20138.","journal-title":"Exp Ther Med."},{"key":"498_CR81","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J-i, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304.","journal-title":"Nat Genet"},{"issue":"5873","key":"498_CR82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1126\/science.1153201","volume":"320","author":"J Vartanian","year":"2008","unstructured":"Vartanian J, Gu\u00e9tard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 2008;320(5873):230\u20133.","journal-title":"Science"},{"issue":"5","key":"498_CR83","doi-asserted-by":"publisher","first-page":"e1000928","DOI":"10.1371\/journal.ppat.1000928","volume":"6","author":"J Vartanian","year":"2010","unstructured":"Vartanian J, Henry M, Marchio A, Susp\u00e8ne R, Aynaud M, Gu\u00e9tard D, et al. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 2010;6(5):e1000928.","journal-title":"PLoS Pathog"},{"key":"498_CR84","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fmicb.2018.00985","volume":"9","author":"FE Leal","year":"2018","unstructured":"Leal FE, Menezes SM, Costa EAS, Brailey PM, Gama L, Segurado AC, Kallas EG, Nixon DF, Dierckx T, Khouri R, Vercauteren J, Galv\u00e3o-Castro B, Raposo RA, Van Weyenbergh J. Comprehensive antiretroviral restriction factor profiling reveals the evolutionary imprint of the ex Vivo and in vivo IFN-\u03b2 response in HTLV-1-associated neuroinflammation. Front Microbiol. 2018;9:985.","journal-title":"Front Microbiol."},{"issue":"1","key":"498_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12977-017-0350-9","volume":"14","author":"S Nozuma","year":"2017","unstructured":"Nozuma S, Matsuura E, Kodama D, Tashiro Y, Matsuzaki T, Kubota R, et al. Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy\/tropical spastic paraparesis. Retrovirology. 2017;14(1):26.","journal-title":"Retrovirology."},{"issue":"15","key":"498_CR86","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1097\/01.aids.0000432474.76873.5f","volume":"27","author":"S Ghezzi","year":"2013","unstructured":"Ghezzi S, Galli L, Kajaste-Rudnitski A, Turrini F, Marelli S, Toniolo D, et al. Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. AIDS. 2013;27(15):2335\u201344.","journal-title":"AIDS."},{"issue":"3","key":"498_CR87","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood-2014-04-572750","volume":"125","author":"Z Dassouki","year":"2015","unstructured":"Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, et al. ATL response to arsenic\/interferon therapy is triggered by SUMO\/PML\/RNF4-dependent Tax degradation. Blood. 2015;125(3):474\u201382.","journal-title":"Blood"},{"issue":"5","key":"498_CR88","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1128\/JVI.02735-15","volume":"90","author":"MF de Castro-Amarante","year":"2015","unstructured":"de Castro-Amarante MF, Pise-Masison CA, McKinnon K, Washington Parks R, Galli V, Omsland M, et al. Human T cell leukemia virus type 1 infection of the three monocyte subsets contributes to viral burden in humans. J Virol. 2015;90(5):2195\u2013207.","journal-title":"J Virol"},{"key":"498_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1742-4690-10-26","volume":"10","author":"T Gramberg","year":"2013","unstructured":"Gramberg T, Kahle T, Bloch N, Wittmann S, M\u00fcllers E, Daddacha W, et al. Restriction of diverse retroviruses by SAMHD1. Retrovirology. 2013;10:26.","journal-title":"Retrovirology."},{"issue":"4","key":"498_CR90","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.chom.2013.09.009","volume":"14","author":"A Sze","year":"2013","unstructured":"Sze A, Belgnaoui S, Olagnier D, Lin R, Hiscott J, van Grevenynghe J. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe. 2013;14(4):422\u201334.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"498_CR91","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.virol.2012.11.012","volume":"436","author":"A Elkaya","year":"2013","unstructured":"Elkaya A, Dersey D, Hill S, Princler G, Heidecker G. Cell\u2013cell transmission allows human T-lymphotropic virus 1 to circumvent tetherin restriction. Virology. 2013;436(1):201\u20139.","journal-title":"Virology."},{"issue":"7","key":"498_CR92","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.3390\/v7072805","volume":"7","author":"R Moles","year":"2015","unstructured":"Moles R, Nicot C. The emerging role of miRNAs in HTLV-1 Infection and ATLL pathogenesis. Viruses. 2015;7(7):4047\u201374.","journal-title":"Viruses."},{"issue":"9","key":"498_CR93","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1074\/jbc.M114.626325","volume":"290","author":"XT Bai","year":"2015","unstructured":"Bai XT, Nicot C. miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection. J Biol Chem. 2015;290(9):5381\u201390.","journal-title":"J Biol Chem"},{"issue":"15","key":"498_CR94","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.82.15.5145","volume":"82","author":"RS Accolla","year":"1985","unstructured":"Accolla RS, Carra G, Guardiola J. Reactivation by a trans-acting factor of human major histocompatibility complex Ia gene expression in interspecies hybrids between an Ia-negative human B-cell variant and an Ia-positive mouse B-cell lymphoma. Proc Natl Acad Sci USA. 1985;82(15):5145\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"498_CR95","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1084\/jem.162.4.1117","volume":"162","author":"RS Accolla","year":"1985","unstructured":"Accolla RS, Scarpellino L, Carra G, Guardiola J. Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes. J Exp Med. 1985;162(4):1117\u201333.","journal-title":"J Exp Med"},{"issue":"1","key":"498_CR96","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1084\/jem.164.1.369","volume":"164","author":"RS Accolla","year":"1986","unstructured":"Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med. 1986;164(1):369\u201374.","journal-title":"J Exp Med"},{"key":"498_CR97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0092-8674(05)80090-X","volume":"75","author":"V Steimle","year":"1993","unstructured":"Steimle V, Otten L, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome. Cell. 1993;75:135\u201346.","journal-title":"Cell"},{"issue":"11","key":"498_CR98","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1286-4579(99)00232-4","volume":"1","author":"J Fontes","year":"1999","unstructured":"Fontes J, Kanazawa S, Nekrep N, Peterlin B. The class II transactivator CIITA is a transcriptional integrator. Microbes Infect. 1999;1(11):863\u20139.","journal-title":"Microbes Infect"},{"key":"498_CR99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fonc.2014.00032","volume":"4","author":"RS Accolla","year":"2014","unstructured":"Accolla RS, Lombardo L, Abdallah R, Raval G, Forlani G, Tosi G. Boosting the MHC class II-restricted tumor antigen presentation to CD4+\u2009T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state. Front Oncol. 2014;4:32.","journal-title":"Front Oncol."},{"issue":"10","key":"498_CR100","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nri1708","volume":"5","author":"W Reith","year":"2005","unstructured":"Reith W, LeibundGut-Landmann S, Waldburger J. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. 2005;5(10):793\u2013806.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"498_CR101","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/1521-4141(2002010)32:10<2783::AID-IMMU2783>3.0.CO;2-E","volume":"32","author":"RS Accolla","year":"2002","unstructured":"Accolla RS, Mazza S, De Lerma Barbaro A, De Maria A, Tosi G. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. Eur J Immunol. 2002;32(10):2783\u201391.","journal-title":"Eur J Immunol"},{"issue":"3","key":"498_CR102","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2003-07-2503","volume":"103","author":"C Casoli","year":"2004","unstructured":"Casoli C, De Lerma Barbaro A, Pilotti E, Bertazzoni U, Tosi G, Accolla RS. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2. Blood. 2004;103(3):995\u20131001.","journal-title":"Blood"},{"issue":"34","key":"498_CR103","doi-asserted-by":"publisher","first-page":"12861","DOI":"10.1073\/pnas.0601589103","volume":"103","author":"G Tosi","year":"2006","unstructured":"Tosi G, Pilotti E, Mortara L, De Lerma Barbaro A, Casoli C, Accolla RS. Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y. Proc Natl Acad Sci USA. 2006;103(34):12861\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1445","key":"498_CR104","first-page":"56","volume":"180","author":"G Franzoso","year":"1994","unstructured":"Franzoso G, Biswas P, Poli G, Carlson L, Brown K, Tomita-Yamaguchi M. A Family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-KB subunit p65 in Vitro and may impair human immunodeficiency virus replication in these cells. J Exp Med. 1994;180(1445):56.","journal-title":"J Exp Med"},{"key":"498_CR105","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-016-0853-5","volume":"14","author":"G Forlani","year":"2016","unstructured":"Forlani G, Turrini F, Ghezzi S, Tedeschi A, Poli G, Accolla RS, et al. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. J Transl Med. 2016;14:94.","journal-title":"J Transl Med."},{"issue":"20","key":"498_CR106","doi-asserted-by":"publisher","first-page":"10719","DOI":"10.1128\/JVI.00813-11","volume":"85","author":"G Tosi","year":"2011","unstructured":"Tosi G, Forlani G, Andresen V, Turci M, Bertazzoni U, Franchini G, et al. Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication. J Virol. 2011;85(20):10719\u201329.","journal-title":"J Virol"},{"key":"498_CR107","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fmicb.2013.00234","volume":"4","author":"G Forlani","year":"2013","unstructured":"Forlani G, Abdallah R, Accolla RS, Tosi G. The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators. Front Microbio. 2013;4:234.","journal-title":"Front Microbio."},{"issue":"7","key":"498_CR108","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1128\/JVI.03000-15","volume":"90","author":"G Forlani","year":"2016","unstructured":"Forlani G, Abdallah R, Accolla RS, Tosi G. The major histocompatibility complex class II transactivator CIITA inhibits the persistent activation of NF-\u03baB by the human T cell lymphotropic virus type 1 Tax-1 oncoprotein. J Virol. 2016;90(7):3708\u201321.","journal-title":"J Virol"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-019-0498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12977-019-0498-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-019-0498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:29:43Z","timestamp":1606523383000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-019-0498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1186\/s12977-019-0498-6","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}